The persistent low levels of ER activity, PR and Bcl‐2 that we observed in fulvestrant relapse samples and the ER phosphorylation and Bcl‐2 detectable at pretreatment in PD patients provide further evidence for functional ER in some fulvestrant resistant tumours. This evidence concerns the gene BCL2 and neoplasm.